The multi-track Next Generation Diagnostics Conference is holdings its eighth annual event in Washington, August 23-26, 2016. The conference website is here.
Within the conference, I have the chance to chair a panel on PAMA. The panel includes Sylvia Trujillo of the AMA, Carol Blackford, Acting Director of the CMS Hospital and Ambulatory Policy Group, Brian Carey of Foley Hoag LLP and Rick Zimmerer, Life Sciences, KPMG.
I am planning to release, "An Innovator's Guide to PAMA" around the time of this panel.
This panel will kick off the conference track "Commercialization of Molecular Diagnostics," which runs August 24-25. The see this track's special webpage, here. Registration for the conference is open.
Details after the break.
The agenda for the Wednesday, August 25, PAMA panel is clipped below.
Other panels and speakers on Wednesday and Thursday will include: a keynote by Elizabeth Mansfield of the FDA, sessions on Value Capture for Advanced Diagnostics, sessions on the role of diagnostics, "From Volume to Value," how big should gene panels be, short courses on Wednesday evening with dinners, talks on "Surviving Payer Review," and how labs and LDTs are affected by payor and provider consolidation. Andrew Fish of AdvMedDX chairs a panel on what evidence is needed, with Liz Mansfield of FDA and speakers from Johns Hopkins and Geisinger. Several speakers, including Sean Tunis, will discuss where Liquid Biopsy is going, and the LBx panel will include Stephanie Schulman from the New York State labs program.
For the full two-day reimbursement agenda, see here.